{"schema_version":"1.0","type":"article","title":"Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.md","lang":"en","date":"2026-06-16","publish_at":"2026-06-16T11:00:00+08:00","updated_at":"2026-06-16","category":"商業分析系列","topic":"商業分析系列","tags":["Eli Lilly","Vaccines","M&A","Prevention medicine","Obesity medicine"],"summary":"Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Beyond obesity","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-01.png"},{"alt":"Why vaccines?","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-02.png"},{"alt":"Capital allocation","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-16）。Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?。https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}